AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine
AstraZeneca Plc has signed a contract with European governments to supply the region with its potential vaccine against the coronavirus, the British drugmaker’s latest deal to pledge its drug to help combat the pandemic.
The contract is for up to 400 million doses of the vaccine, developed by the University of Oxford, the company said, adding that it was looking to expand manufacturing of the vaccine, which it said it would provide for no profit during the pandemic.
The vaccine is still in clinical trials. If the trial results convince regulators the vaccine is safe and effective, deliveries would be expected to start by the end of 2020.
Source: Jordan News Agency